Roles in PharmNovo: Chief executive officer, Business advisor and Director of the board.
Education: Bachelor’s degree in International Business Administration from the University of Lund.
Work experience: 30 years of experience from International business in various industries and has vast experience in developing and transforming mid-size businesses. In 2003–2007 Per was VP Marketing & Sales for Nybron Flooring, European market leader in parquet flooring, with HQ in Switzerland and during 2008–2017 he was CEO at Elfa International with HQ in Malmö, Sweden.
Roles in PharmNovo: Business advisor and Director of the board.
Education: Ph.D. Trained in neuropharmacology and holds a Ph.D. from the University of Nottingham (UK).
Work experience: Co-founded Afferent Pharmaceuticals, Inc. in 2009 and served as its Chief Scientific Officer until it’s take over by Merck in 2016. Dr. Ford has more than 20 years of research and development experience at Roche (where he served as Vice President) Syntex and Afferent, having led the progression of several novel drug candidates into early clinical development, focused particularly in the areas of pain and genitourinary therapeutics. He was also responsible for the development of AF-219, a selective P2X3 antagonist for the treatment of pathologic cough.
Roles in PharmNovo: Business and scientific advisor.
Education: Medical education from Copenhagen University from 1981. 6 years of hospital service within surgery, anesthesiology and internal medicine.
Work experience: Peder has more than 25 years of experience from large pharma, medium pharma and small/virtual biotech pharma. He has worked within oncology, diabetes, neurology, dermatology and was in his earlier days as consultant involved in testing cannabinol for neuropathic pain. He has established his own company and sold it to larger pharma. He has held senior positions in Orion Pharma, Novo Nordisk, Astion Pharma and Forward Pharma. He has held numerous meetings with both FDA, EMA, European agencies as well as Australian and New Zealand authorities. With Forward Pharma he was as CEO/COO heading all development and IP activities and was instrumental in the IPO on the NY Nasdaq October 2014 (raised 235M USD). Forward Pharma did also complete a license deal with Biogen Idec with a down payment of 1.25B USD. He holds currently the position as CEO at Biosergen AS, Norway.
Role in PharmNovo: Business advisor.
Education: MSc in Pharmacy from Copenhagen University in 1992, DK; Exec. MBA from Imperial College, London, UK in 2012.
Work experience: Tine is currently based in US and has 25 years of experience in pharmaceutical industry. She has worked at Ferring Pharmaceuticals in US and in Denmark for the past 18 years where she directs integrated clinical development programs from early stage to life cycle management in uro-/oncology with responsibility for the design and development of novel strategies from early stage and through marketing authorization, followed by market access in R&D. Her key focus is within CMC and clinical development, directing regulatory actions, including NDA submissions and FDA advisory committee, interpretation of scientific data, building the value story and development of new businesses. Tine has prior experience in the therapeutic fields of Parkinson’s disease, epilepsy, diabetes, and migraine headaches within large pharma companies (Novo, GSK, and Orion).